AstraZeneca to pay up to $2 billion to license cardiovascular drug
Read Time:5 Second
AstraZeneca on Monday said it will pay up to $2 billion to license a cardiovascular drug.
A record number of consumers expect mortgage rates to fall over the next year. They’re also bracing for an increase...
“Many of those owners were not insured or underinsured.”
A Melius Research analyst says “you still get some eye rolls when you reiterate this buy,” but the setup for...
A Jefferies analyst says it will take time for smartphone technology to truly support AI. That means sales expectations for...
The Phase 3 trial of Apitegromab showed statistically significant improvement in motor function.
The key U.S. Treasury yield reached 4% on Monday, as investors continued to reassess their view of the U.S. economy...
Average Rating